Pharmacogenomic Inequalities: Strategies for Justice in Biomedical Research and Healthcare

Giovanni De Grandis

About author

Dr. Giovanni De Grandis
Postdoctoral researcher
Reset research group on the ethos of technology
Department of Philosophy and Religious Studies
Norwegian University of Science and Technology

E-mail: giovanni.de.grandis@ntnu.no

Abstract


The paper discusses the possibility that the benefits of pharmacogenomics will not be distributed equally and will create orphan populations. I argue that since these inequalities are not substantially different from those produced by ‘traditional’ drugs and are not generated with the intention to discriminate, their production needs not be unethical. Still, the final result is going against deep-seated moral feelings and intuitions, as well as broadly accepted principles of just distribution of health outcomes and healthcare. I thus propose two provisos that would prevent the most offensive outcomes and moderate the scope of the produced inequalities. The first proviso rejects pharmacogenomics innovations that worsen existing group inequalities and aggravate the disadvantage of communities with a history of discrimination. The second proviso requires that there is a strategy in place to even out as much as possible the distribution of benefits in the future and that a system of compensations (in terms of healthcare services) is in place for pharmacogenomic orphans. Given that only one moral problem generated by pharmacogenomics has been tackled, the list of provisos might be expanded when other issues are considered.

Full Text:

PDF


References


  1. S. Anand, F. Peter and A.K. Sen, Public health, ethics, and equity, Oxford University Press, Oxford 2004.
  2. G. Annas and S. Elias, Genomics Messages. How the Evolving Science of Genetics affects our Health, Families, and Future, HarperOne, New York 2015.
  3. M. Bartley, Health inequality: an introduction to theories, concepts and methods, Polity Press, Cambridge, UK, Malden, MA 2003.
  4. R. Bayer and S. Galea, “Public health in the precision-medicine era,” New England Journal of Medicine (373/6) 2015, p. 499–501.
  5. Department for Business Innovation and Skills, “Life Sciences in the UK – Economic analysis and evidence for ‘Life Sciences 2010: Delivering the Blueprint’,” Economic Paper NO. 2, 2010.
  6. D. Black, J. Morris, C. Smith and P. Townsend, Inequalities in health: report of a Research Working Group, Department of Health and Social Security, London 1980.
  7. M.M. Braun, S. Farag-El-Massah, K. Xu and T.R. Coté, “Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years,” Nature Reviews Drug Discovery (9/7) 2010, p. 519–522.
  8. P. Braveman, “Health disparities and health equity: concepts and measurement,“ Annual Review of Public Health (27) 2006, p. 167–194.
  9. H. Brody, Hooked. Ethics, the Medical Profession, and the Pharmaceutical Industry, Rowman & Littlefield, Lanham MD 2007.
  10. A.E. Buchanan, A. Califano, J.P. Kahn, B.A. Brody, J.A. Robertson, and E. McPherson, “Pharmacogenetics: ethical issues and policy options,” Kennedy Institute of Ethics Journal (12/1) 2002, p. 1–15.
  11. Experts in Chronic Myeloid Leukemia, “The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts,” Blood (121/22) 2013, p. 4439–4442.
  12. E.G. Cohn, G.E. Henderson and P.S. Appelbaum, “Distributive justice, diversity, and inclusion in precision medicine: what will success look like?“ Genetics in Medicine (19) 2017, p. 157–159.
  13. A.J. Culyer and A. Wagstaff, “Equity and equality in health and health care,“ Journal of health economics (12/4) 1993, p. 431–457.
  14. N. Daniels, Just health care, Cambridge University Press, Cambridge 1985.
  15. N. Daniels, Just health: meeting health needs fairly, Cambridge University Press, Cambridge 2007.
  16. G. De Grandis and V. Halgunset, “Conceptual and Terminological Confusion Around Personalised Medicine: A Coping Strategy,” BMC Medical Ethics (17/43) 2016, p. 1–12.
  17. G.J. Downing, “Policy perspectives on the emerging pathways of personalized medicine,” Dialogues Clinical Neuroscience (11/4) 2009, p. 377–387.
  18. L. Drew “Pharmacogenetics: The right drug for you,” Nature (537/7619) 2016, p. 60–62.
  19. R.A. Dudley and H.S. Luft, “Goals, targets, and tactics: Making health care policy decisions explicit,” Journal of Health Politics, Policy and Law (24/4) 1999, p. 705–713.
  20. T. Duster, “A post‐genomic surprise. The molecular reinscription of race in science, law and medicine,“ The British journal of sociology (66/1) 2015, p. 1–27.
  21. European Science Foundation - European Medical Research Council, “A stronger Biomedical Research for a Better European Future,” White Paper (II) 2011.
  22. J.P. Evans and M.J. Khoury, “The arrival of genomic medicine to the clinic is only the beginning of the journey,” Genetics in Medicine (15/4) 2013, p. 268–269.
  23. L.M. Fleck, Just Caring. Health Care Rationing and Democratic Deliberation, Oxford University Press, New York 2007.
  24. L.M. Fleck, “Just caring: Assessing the ethical and economic costs of personalized medicine,” Urologic Oncology: Seminars and Original Investigations (32/2) 2014, p. 202–206.
  25. M.W. Foster, J.J. Mulvihil and R.R. Sharp, “Investments in cancer genomics: Who benefits and who decides,” American journal of public health (96/11) 2006, p. 1960–1964.
  26. O. Gassmann, G. Reepmeyer and M. von Zedtwitz, Leading pharmaceutical innovation: trends and drivers for growth in the pharmaceutical industry, Springer, Berlin and Heidelberg 2008.
  27. S. Gibson and B. von Tigerstrom, “Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada,“ Journal of Law and the Biosciences (2/2) 2015, p. 263–291.
  28. G.S. Ginsburg and H.F. Willard, “Genomic and personalized medicine: foundations and applications,” Translational Research (154/6) 2009, p. 277–287.
  29. M. Goozner, The $ 800 Million Pill: The Truth Behind the Cost of New Drugs, University of California Press, Berkeley – Los Angeles – London 2004.
  30. G. Gronowicz, Personalized Medicine. Promises and Pitfalls, CRC Press, Boca Raton – London – New York 2016.
  31. A. Harvey, A. Brand, S.T. Holgate, L.V. Kristiansen, H. Lehrach, A. Palotie and B. Prainsack, “The future of technologies for personalised medicine,” New biotechnology (29/6) 2012, p. 625–633.
  32. M. Herder, “What Is the Purpose of the Orphan Drug Act?“ PLoS medicine (14/1) 2017, e1002191.
  33. M.M. Hopkins, P.A. Martin, P. Nightingale, A. Kraft, and S. Mahdi, “The myth of the biotech revolution: An assessment of technological, clinical and organisational change,“ Research policy (36/4) 2007, p. 566–589.
  34. P. Hunt and R. Khosla, “Are Drug Companies Living Up to Their Human Rights Responsibilities? The Perspective of the Former United Nations Special Rapporteur (2002-2008),” PLoS Medicine (7/9) 2010, e1000330.
  35. A.M. Issa, “Ethical perspectives on pharmacogenomic profiling in the drug development process,” Nature reviews Drug discovery (1/4) 2002, p. 300–308.
  36. A.M. Issa, “10 years of personalizing medicine: how the incorporation of genomic information is changing practice and policy,” Personalized Medicine (12/1) 2015, p. 1–3.
  37. J.E. James, “Personalised medicine, disease prevention, and the inverse care law: more harm than benefit?” European journal of epidemiology (29/6) 2014, p. 383–390.
  38. A.C.J.W. Janssens and P.A. Deverka, “Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing,” Clinical Pharmacology & Therapeutics (96/6) 2014, p. 652–654.
  39. J.A. Johnson, “Pharmacogenetics in clinical practice: how far have we come and where are we going?” Pharmacogenomics (14/7) 2013, p. 835–843.
  40. D.S. Jones, “How personalized medicine became genetic, and racial: Werner Kalow and the formations of pharmacogenetics,” Journal of the history of medicine and allied sciences (68/1) 2011, p. 1–48.
  41. A.R. Jonsen, A Short History of Medical Ethics, Oxford University Press, New York 2000.
  42. M.J. Joyner and N. Paneth, “Seven questions for personalized medicine”, JAMA 314 (10) 2015, p. 999–1000.
  43. M.J. Khoury and S. Galea, “Will Precision Medicine Improve Population Health?” JAMA 316 (13) 2016, p. 1357–1358.
  44. R. Langreth and M. Waldholz, “New Era of Personalized Medicine Targeting Drugs for Each Unique Genetic Profile,” The oncologist (4/5) 1999, p. 426–427.
  45. L. Leyens, D. Horgan, J.A. Lal, K. Steinhausen, K. Satyamoorthy and A. Brand, “Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective,” Personalized Medicine (11/7) 2014, p. 641–649.
  46. J.P. Mackenbach, Health inequalities: Europe in profile, UK Presidency of the EU 2005, s.l. 2006.
  47. P. Martin, G. Lewis, A. Smart and A. Webster, False positive? The commercial and clinical development of pharmacogenetics, University of Nottingham, University of York & University of Bath, Nottingham & York 2006.
  48. P. Martin, M. Hopkins, P. Nightingale & A. Kraft, On a Critical Path. Genomics, the Crisis of Pharmaceutical Productivity and the Search for Sustainability, [in:] Handbook of Genetics and Society. Mapping the New Genomic Era, P. Atkinson, P. Glasner & M. Lock (eds), Routledge, Abingdon UK and New York 2013, p. 145–162.
  49. National Research Council, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease, The National Academies Press, Washington, DC 2011.
  50. B.P. O’Sullivan, D.M. Orenstein and C.E. Milla, “Pricing for orphan drugs: will the market bear what society cannot?” Jama (310/13) 2013, p. 1343–1344.
  51. K. Peterson-Iyer, “Pharmacogenomics, ethics, and public policy,” Kennedy Institute of Ethics Journal (18/1) 2008, p. 35–56.
  52. A. Pokorska-Bocci, A. Stewart, G.S. Sagoo, A. Hall, M. Kroese and H. Burton, “’Personalized medicine’: what's in a name?” Personalized Medicine (11/2) 2014, p. 197–210.
  53. M. Powers and R. Faden, Social Justice. The Moral Foundations of Public Health and Health Policy, Oxford University Press, Oxford 2005.
  54. B. Prainsack and A. Buyx, Solidarity in Biomedicine and Beyond, Cambridge University Press, Cambridge 2017.
  55. V. Prasad, “The precisiononcology illusion,” Nature 537 (7619), S63, 2016.
  56. A.K. Rai, “Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis,” Social Philosophy and Policy (19/02) 2002, p. 246–270.
  57. J.A. Robertson, B. Brody, A. Buchanan, J. Kahn, and E. McPherson, “Pharmacogenetic challenges for the health care system,” Health Affairs (21/4) 2002, p. 155–167.
  58. M.A. Rothstein and P.G. Epps, “Ethical and legal implications of pharmacogenomics,” Nature Reviews Genetics (2/3) 2001, p. 228–231.
  59. J. Sachs, “The Drug that Is Bankrupting America”, The Huffington Post 16.02.2015, URL = http://www.huffingtonpost.com/jeffrey-sachs/the-drug-that-is-bankrupt_b_6692340.html [15.12.2016].
  60. M. Shaw, D. Dorling, D. Gordon, and G.D. Smith, The widening gap: health inequalities and policy in Britain, Policy Press, Bristol 1999.
  61. S. Simoens, D. Cassiman, M. Dooms and E. Picavet, “Orphan Drugs for Rare Diseases,” Drugs 72 (11) 2012, p. 1437–1443.
  62. R.L. Slaughter, “Translation of pharmacogenetics to clinical practice: what will it take?” Expert review of clinical pharmacology (5/2) 2010, p. 101–103.
  63. A. Smart, P. Martin and M. Parker, “Tailored medicine: whom will it fit? The ethics of patient and disease stratification,” Bioethics (18/4) 2004, p. 322–343.
  64. A. Squassina, M. Manchia, V.G. Manolopoulos, M. Artac, C. Lappa-Manakou, S. Karkabouna, K. Mitropoulos, M. Del Zompo and G.P. Patrinos, “Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice,” Pharmacogenomics (11/8) 2010, p. 1149–1167.
  65. R. Tutton, “Personalizing medicine: Futures, present and past,” Social Science and Medicine (75) 2012, p. 1721–1728.
  66. United Nations Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art. 12 of the Covenant), Geneva 2000.
  67. H.A. Washington, Deadly monopolies: the shocking corporate takeover of life itself—and the consequences for your health and our medical future, Doubleday, New York 2011.
  68. O. Wellman-Labadie and Y. Zhou, ”The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?” Health Policy (95/2) 2010, p. 216–228.
  69. R. Wilkinson and M. Marmot, The solid facts. Social determinants of health, World Health Organization Regional Office for Europe, Copenhagen 2005.

DOI:

http://dx.doi.org/10.13153/diam.51.2017.1036

Article links:

Default URL: http://www.diametros.iphils.uj.edu.pl/index.php/diametros/article/view/1036
English abstract URL: http://www.diametros.iphils.uj.edu.pl/index.php/diametros/article/view/1036/en

Share:






All works are licensed under a Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) License.